Skip to main content Accessibility help
×
Home
  • Print publication year: 2014
  • Online publication date: October 2014

Chapter 41 - Patient with migraine headaches

from Section 5 - Headaches and Facial Pain

Related content

Powered by UNSILO

References

1. Stang PE, Osterhaus JT, Celentano DD. Migraine: patterns of healthcare use. Neurology. 1994;44(6):S47–S55.
2. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646–657.
3. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache. 2001;41(7):638–645.
4. Pietrobon D. Migraine: new molecular mechanisms. The Neuroscientist. 2005;11(4):373–386.
5. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. JAMA. 1992;267(1):64–69.
6. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999;159(8):813.
7. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995;1(7):658–660.
8. Goadsby PJ, Lipton RB, Ferrari MD. Migraine: current understanding and treatment. N Engl J Med. 2002;346(4).
9. Moskowitz MA. Pathophysiology of headache: past and present. Headache. 2007;47 (Suppl 1):S58–63.
10. International Headache Society Classification Subcommittee. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24(Suppl 1):9–160.
11. Kruit MC, van Buchem MA, Launer LJ, Terwindt GM, Ferrari MD. Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: the population-based MRI CAMERA study. Cephalalgia. 2010;30(2):129–136.
12. Buring JE, Hebert P, Romero J, et al. Migraine and subsequent risk of stroke in the Physicians’ Health Study. Arch Neurol. 1995;52(2):129.
13. Kurth T, Schurks M, Logroscino G, Gaziano JM, Buring JE. Migraine, vascular risk, and cardiovascular events in women: prospective cohort study. BMJ. 2008;337:a636.
14. Schurks M, Rist PM, Bigal ME, et al. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ. 2009;339:b3914.
15. Stang P, Carson A, Rose K, et al. Headache, cerebrovascular symptoms, and stroke: The Atherosclerosis Risk in Communities Study. Neurology. 2005;64(9):1573–1577.
16. Spector JT, Kahn SR, Jones MR, et al. Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med. 2010;123(7):612–624.
17. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine. Drugs. 2000;60(6):1259–1287.
18. Bartsch T, Knight YE, Goadsby PJ. Activation of 5-HT1B/1D receptor in the periaqueductal gray inhibits nociception. Ann Neurol. 2004;56(3):371–381.
19. Ferrari M, Goadsby P, Roon K, Lipton R. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22(8):633–658.
20. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol. 2004;55(1):19–26.
21. Rapoport AM, Bigal ME, Tepper SJ, Sheftell FD. Intranasal medications for the treatment of migraine and cluster headache. CNS Drugs. 2004;18(10):671–685.
22. Schulman EA. Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea. Headache. 2012;52(2):204–212.
23. Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener H-C. Features of medication overuse headache following overuse of different acute headache drugs. Neurology. 2002;59(7):1011–1014.
24. Young WB, Mannix L, Adelman JU, Shechter AL. Cardiac risk factors and the use of triptans: a survey study. Headache. 2000;40(7):587–591.
25. Boyer EW, Shannon M. The serotonin syndrome. New Engl J Med. 2005;352(11):1112–1120.
26. Dunkley E, Isbister G, Sibbritt D, Dawson A, Whyte I. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635–642.
27. Shapiro RE, Tepper SJ. The serotonin syndrome, triptans, and the potential for drug–drug interactions. Headache. 2007;47(2):266–269.
28. Evans RW, Tepper SJ, Shapiro RE, Sun-Edelstein C, Tietjen GE. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society Position Paper. Headache. 2010;50(6):1089–1099.
29. Sprenger T, Goadsby P. Migraine pathogenesis and state of pharmacological treatment options. BMC Med. 2009;7(1):71.
30. Waeber C, Moskowitz MA. Therapeutic implications of central and peripheral neurologic mechanisms in migraine. Neurology. 2003;61(8 suppl 4):S9–S20.
31. Lipton R, Stewart W, Sawyer J, Edmeads J. Clinical utility of an instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire. Headache. 2001;41(9):854–861.
32. Silberstein SD, Dodick DW, Saper J, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia. 2012;32(16):1165–1179.
33. Reed K, Will K, Chapman J, Richter E. Combined occipital and supraorbital neurostimulation for chronic migraine headaches: an extended case series. Paper presented at 15th Congress of the International Headache Society 2011.
34. Condò M, Posar A, Arbizzani A, Parmeggiani A. Riboflavin prophylaxis in pediatric and adolescent migraine. J Headache Pain. 2009;10(5):361–365.
35. Ziaei S, Kazemnejad A, Sedighi A. The effect of vitamin E on the treatment of menstrual migraine. Medical Science Monitor. 2009;15(1):CR16.
36. Sandor P, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005;64(4):713–715.
37. Peres M, Zukerman E, da Cunha Tanuri F, Moreira F, Cipolla-Neto J. Melatonin, 3 mg, is effective for migraine prevention. Neurology. 2004;63(4):757.
38. Miano S, Parisi P, Pelliccia A, et al. Melatonin to prevent migraine or tension-type headache in children. Neurol Sci. 2008;29(4):285–287.
39. Peres MF, Masruha MR, Zukerman E, Moreira-Filho CA, Cavalheiro EA. Potential therapeutic use of melatonin in migraine and other headache disorders. Expert Opin Investig Drugs. 2006;15(4):367–375.